Orion Infusion Limited (DSE:ORIONINFU)

Market Cap	6.31B -22.8%
Revenue (ttm)	665.43M -15.0%
Net Income	37.47M -9.9%
EPS	1.84 -9.9%
Shares Out	20.36M
PE Ratio	168.29
Forward PE	n/a
Dividend	2.00 (0.64%)
Ex-Dividend Date	Dec 2, 2025

Volume	104,593
Average Volume	278,342
Open	315.00
Previous Close	312.30
Day's Range	308.70 - 316.90
52-Week Range	303.30 - 587.50
Beta	-1.69
RSI	37.78
Earnings Date	Apr 29, 2026

About Orion Infusion

Orion Infusion Limited manufactures and sells large volume parenteral and other lifesaving injectable products in Bangladesh. The company offers I.V. rehydration, electrolyte, and acidosis solutions; ranitidine I.V. infusion; anti-microbial products; metronidazole I.V; pure steam generated fluids; and amino acids solution. It also provides sterile and nonpyrogenic solution, such as Dextrolac, Dianak, Hartman, Manisol, Plasmasol, and Proliv; hypertonic solution, including Dextrosal, Electrodex-10, Fructose – 10, Orlev, Ortac; Dextropac, an isoto...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 563
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ORIONINFU

Financial Performance

In fiscal year 2025, Orion Infusion's revenue was 664.92 million, a decrease of -19.64% compared to the previous year's 827.42 million. Earnings were 35.02 million, a decrease of -17.27%.